A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Beata Holkova(Virginia Commonwealth University), Steven Grant(Virginia Commonwealth University)

Clinical Cancer Research

October 7, 2015

10.1158/1078-0432.ccr-15-1076

Cited by 48

Related Papers

Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation

|Journal of Biological Chemistry|2005|284

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

|Clinical Cancer Research|2009|230

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

|Blood|2004|123

The Bruton tyrosine kinase (<scp>BTK</scp>) inhibitor <scp>PCI</scp>‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (<scp>DLBCL</scp>) and mantle cell lymphoma (<scp>MCL</scp>) cells sensitive or resistant to bortezomib

|British Journal of Haematology|2013|84

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells <i>In Vitro</i> and <i>In Vivo</i>

|Clinical Cancer Research|2011|76